BPC-157

• BPC-157 is a synthetic 15-amino-acid peptide whose sequence was described as a partial sequence of a protein ('body protection compound') isolated from gastric juice. Most of the published work comes from a single research group, and reviews have noted that independent replication is limited [1][2].
• Studies have been published mainly in rodent models of gastrointestinal, musculoskeletal and vascular injury, together with a smaller number of cell-culture studies [3][4].

Identity values are confirmed per lot on the certificate of analysis. Salt/counter-ion form (e.g. acetate or TFA) is stated on the COA where applicable.

• Nitric-oxide (NO) system: a series of rodent studies examined interactions between BPC-157 and NO-system modulators (L-NAME, L-arginine) [5].
• VEGFR2–Akt–eNOS signalling: in endothelial cell culture and a rat hind-limb ischaemia model, BPC-157 was reported to up-regulate VEGFR2 expression and promote VEGFR2 internalisation [6].
• FAK–paxillin and F-actin: in cultured tendon fibroblasts, BPC-157 was reported to increase FAK and paxillin phosphorylation and F-actin formation [7].
• Tendocyte growth in vitro: one study reported that BPC-157 opposed the growth-inhibiting effect of 4-hydroxynonenal in cultured tendocytes [8].
• A single, definitive molecular target or receptor has not been established.

• No completed, published randomised controlled trial of BPC-157 was identified. A 2025 systematic review in orthopaedic sports medicine found only level IV–V evidence (case series and similar reports) in humans and reported that no clinical safety data were found [9].
• BPC-157 is not an approved medicine in the UK, the US or the EU. A 2025 literature and patent review notes that it has not been approved by the FDA or other regulators because of insufficient clinical study [4].

• Reviews report that preclinical studies in animals have described few adverse findings, but formal toxicology and human safety data are limited [9][2].
• A 2025 narrative review emphasises that products from non-regulated sources carry contamination and quality risks, and that human data are minimal [2].

• Most studies come from one research group, and independent replication is limited [1].
• Human evidence is limited to small, uncontrolled reports [9].
• The molecular target is unknown, and pharmacokinetic data are sparse.

Store at −20 °C. Protect from light.

Store lyophilised material sealed at −20 °C or below, protected from light and moisture. Allow the vial to equilibrate to room temperature before opening to limit condensation.

• Allow the sealed vial to reach room temperature before opening to limit condensation.
• Any solutions should be prepared only for in-vitro laboratory work under your own validated protocol; aliquoting limits repeated freeze–thaw cycles.
• Handle with standard laboratory PPE in line with your risk assessment and the Safety Data Sheet (SDS). Britpep does not provide preparation or administration guidance.